Coloplast interim Chief Executive Lars Rasmussen will step down from the company's board of directors, the latest leadership change at the Danish medical device maker as it implements a new strategy.
Rasmussen will not stand for re-election at the annual general meeting on Dec. 4, the company said Thursday.
He will continue to serve as interim CEO, a role he assumed in May after the departure of Kristian Villumsen, until a permanent successor is appointed.
Rasmussen previously served as Coloplast's CEO for a decade until 2018, when he became chairman of the board.
“It has been an honor and privilege to serve this company for most of my life, and I have decided to step back from my board responsibilities at a time when the company is well positioned for the future,” Rasmussen said in a statement.
The company said its board will propose the election of Niels B. Christiansen as a new member, with the expectation that he will be appointed chair by December 2026 at the latest.
Jette Nygaard-Andersen will continue as interim chair.
The management shuffle follows the September launch of Coloplast's new five-year strategy, dubbed "Impact4," which tempered its long-term growth forecast.
The search for a new permanent CEO is progressing according to plan, the company said.
More from this issuer
Related coverage
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets as it navigates a period of strategic and leadership transition.
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets, and forecast a similar performance for the year ahead as it implements a new strategy.
Danish medical device maker Coloplast on Tuesday unveiled a new five-year strategy that tempers its long-term growth forecast.
Danish medical device maker Coloplast on Tuesday tempered its long-term growth forecast as it unveiled a new five-year strategy, dubbed "Impact4."